Loading
UFP Technologies Inc Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by LATAILLE RONALD J, was filed 27 Feb 2025.
UFP Technologies Inc: what insiders have been doing
Headquartered in Georgetown, United States, UFP Technologies Inc belongs to the Healthcare & Pharma sector and traces its origins to 1963. Filings by its managers are published through SEC (Form 4). The last twelve months, up to 22 October 2026, brought 57 filings signed by 16 insiders.
No insider bought on the market over the period, while 7 insiders filed 25 sales totalling €11.8M. Biggest ticket of the year: €2.2M, sold by Bailly R Jeffrey and made public on 10 August 2026 (0.11% of market cap).
Across the 3,171 companies tracked on its exchange, the median is 24 filings; at 57 filings, this issuer sits above that mark. Looking back to 2016, when coverage begins, insiders filed 6 purchases and 276 sales. In its latest annual report filed with the SEC (10-K, fiscal year ended 31 December 2025), the company reported revenue of 602.8 m USD and net income of 68.3 m USD.
Filings reach the SEC (Form 4) feed a median of 2 days after the trade. The legal deadline for a Form 4 is two business days after the transaction. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives.
These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
652
Thresholds
n/a
Buy Volume
€260,338
6 ops. · all time
Sell Volume
€110M
276 ops. · all time
Who traded when
BuySaleR. Jeffrey Bailly29 sales
Litterio Christopher P.12 sales
Daniel C. Croteau11 sales
Symeria Hudson5 sales
Cynthia L. Feldmann4 sales
Jason Holt3 sales
+2 other insiders
Since the insiders bought
- -10.2%Entry US$227.59 · Close at T+365 US$204.30
- +140.7%Entry US$142.70 · Close at T+365 US$343.49
- +31.6%Entry US$55.01 · Close at T+365 US$72.40
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 11,902 of 26,246 companies
53.9
score / 100
Value43
Quality65
FCF yld3.5%
Earn yld3.0%
EV/EBITDA21.5x
ROE17%
Gross mgn28%
Net mgn11%
Debt/EBITDA1.4x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$290.11
Analyst consensus
2 analysts2.25/5
US$350.00Target US$355.00(+22%)US$360.00
Income statement
RevenueUS$602.8M
Gross profitUS$170.4M28% margin
EBITDAUS$111.5M18% margin
Net incomeUS$68.3M11.4% margin
Valuation
PER (trailing)31.3x
PER (forward)24.4x
P/Book4.9x
Beta1.03
Balance sheet & cash
Market capUS$2.2B
Total debtUS$154.5M
Free Cash FlowUS$79M
Debt / Equity29%
Profitability & ownership
ROE17.1%
ROA9.1%
% insiders3.8%
% institutions124.0%
Last declaration on 27 August 2026
Declarations652 total
3,650 shares@ US$303.970.047% mcap26.0% of flowCommon Stock, $.01 Par ValueSEC:0002084956-26-000064:0
3,350 shares@ US$305.070.044% mcap23.9% of flowCommon Stock, $.01 Par ValueSEC:0002084956-26-000064:1
7,000 shares@ US$305.850.091% mcap50.1% of flowCommon StockSEC144:0001959173-26-006430
298 shares@ US$319.110.0040% mcap9.8% of flowCommon Stock, $.01 Par ValueSEC:0002084956-26-000062:0
1,000 shares@ US$324.260.014% mcap100.0% of flowCommon Stock, $.01 Par ValueSEC:0002084956-26-000058:0
703 shares@ US$167.980.0050% mcap12.2% of flowCommon Stock, $.01 Par ValueSEC:0002084956-26-000060:0
493 shares@ US$260.920.0055% mcap13.3% of flowCommon Stock, $.01 Par ValueSEC:0002084956-26-000060:1
1,926 shares@ US$324.580.027% mcap64.7% of flowCommon Stock, $.01 Par ValueSEC:0002084956-26-000060:2
2,349 shares@ US$266.13270.028% mcap100.0% of flowCommon StockSEC144:0001628280-26-057058
1,000 shares@ US$324.260.014% mcap53.1% of flowCommon StockSEC144:0001628280-26-056747
5,771 shares@ US$315.530.078% mcap4.4% of flowCommon Stock, $.01 Par ValueSEC:0002084956-26-000056:0
6,866 shares@ US$316.580.093% mcap5.2% of flowCommon Stock, $.01 Par ValueSEC:0002084956-26-000056:1
374 shares@ US$317.270.0051% mcap0.3% of flowCommon Stock, $.01 Par ValueSEC:0002084956-26-000056:2
7,877 shares@ US$318.120.11% mcap6.0% of flowCommon Stock, $.01 Par ValueSEC:0002084956-26-000054:0
2,805 shares@ US$320.050.039% mcap2.2% of flowCommon Stock, $.01 Par ValueSEC:0002084956-26-000054:1
542 shares@ US$315.060.0074% mcap0.4% of flowCommon Stock, $.01 Par ValueSEC:0002084956-26-000054:2
4,471 shares@ US$318.210.061% mcap3.4% of flowCommon Stock, $.01 Par ValueSEC:0002084956-26-000054:3
1,100 shares@ US$317.000.015% mcap41.1% of flowCommon Stock, $.01 Par ValueSEC:0002084956-26-000052:0
1,100 shares@ US$317.000.015% mcap100.0% of flowCommonSEC144:0001628280-26-054056
28,706 shares@ US$320.510.40% mcap100.0% of flowCommonSEC144:0001949846-26-000471
1,000 shares@ US$322.000.014% mcap16.2% of flowCommonSEC144:0001974078-26-000293
1,200 shares@ US$239.290846.9% of flowCommonSEC144:0001628280-26-042801
750 shares@ US$223.870.0072% mcap0.4% of flowCommon Stock, $.01 Par ValueSEC:0002084956-26-000048:1
1,787 shares0Common Stock, $.01 Par ValueSEC:0002084956-26-000048:0
802 shares0Common Stock, $.01 Par ValueSEC:0002084956-26-000037:0
25 of 652 declarations
About UFP Technologies Inc
UFP Technologies, Inc. is a US-based industrial healthcare manufacturing company listed on the NASDAQ under the ticker UFPT. Headquartered in Newburyport, Massachusetts, United States, the company was founded in 1963 and has evolved from a protective packaging business into a specialized contract development and manufacturing organization. Today, it focuses primarily on single-use and single-patient medical devices, making it a niche supplier within the medical technology supply chain rather than a broad-based diversified manufacturer.
The company’s core business centers on design, engineering, and manufacturing solutions for the medical market. Its products and components are used in minimally invasive surgery, infection prevention, wound care, wearables, orthopedic soft goods, and orthopedic implants. In practical terms, UFP Technologies acts as an outsourcing partner to major medical-device OEMs, helping customers move from concept and design through industrialization, production, and delivery. This model tends to support sticky customer relationships, recurring program revenue, and a value proposition based on technical know-how rather than pure price competition.
Read moreShow less
From a competitive standpoint, UFP Technologies benefits from specialization, application engineering, and a multi-site manufacturing footprint. The company describes itself as an important link in the medical-device supply chain and a valued outsourcing partner to many of the world’s leading medical-device manufacturers. That positioning creates meaningful barriers to entry, especially where customers require validated processes, materials expertise, regulatory discipline, and reliable transfer of production across facilities.
Recent developments have been positive and strategically relevant. In 2025, UFP Technologies reported record full-year results, with strong growth in revenue and net income, and it continued to expand through targeted acquisitions. Management also highlighted new program launches and additional manufacturing capacity to support future growth. In early 2026, the company reported another solid quarter and said its recent acquisitions were performing well, with integrations essentially complete. Another key event for investors is leadership transition: the company announced that CEO R. Jeffrey Bailly is scheduled to retire at the annual meeting on June 4, 2026. For investors following Form 4 insider transactions, that combination of growth, acquisition activity, and succession planning is especially important to monitor.
